OUR PURPOSE IS SIMPLE:
Patients fighting chronic diseases are often denied access to life-saving treatments.
ICERWatch gives patients a voice to fight back.
Patients Rising Now is welcomes the opportunity to provide recommendations and comments about the pros and cons of ICER’s August 21st document outlining proposed changes
Institute for Patient Access & Affordability Comments on ICER Oral Semaglutide for Type 2 Diabetes: Draft Evidence Report
Institute for Patient Access & Affordability (IPAA) is a new program division of Patients Rising with the mission to provide patient-powered pathways to help both
The Institute for Clinical and Economic Review, which receives support from insurance companies, has begun its financial analysis of how two new SCD treatments, crizanlizumab and voxelotor, will affect insurance profits.
SSTs are considered game changers in medicine with the potential to cure rare, fatal or chronic diseases, such as Alzheimer’s disease.
Massachusetts state representatives, have introduced legislation that would block insurance companies, hospitals, health maintenance organizations, and the state’s Medicaid program, MassHealth, from using “quality-adjusted life years” in providing care to patients.